Centiva Capital’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-22,500
Closed -$4.14M 1675
2025
Q4
$4.14M Buy
+22,500
New +$3.95M 0.03% 296
2023
Q4
Sell
-7,500
Closed -$1.02M 1798
2023
Q3
$1.02M Buy
7,500
+5,000
+200% +$683K 0.02% 635
2023
Q2
$358K Buy
+2,500
New +$368K 0.01% 1015
2020
Q1
Sell
-2,500
Closed -$249K 619
2019
Q4
$249K Hold
2,500
0.01% 608
2019
Q3
$223K Buy
+2,500
New +$217K 0.01% 491

Other funds holding AZN

Centiva Capital's AZN Position: Q1 2026 in Review

Centiva Capital sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 3,098 shares — an estimated $570K sold.

Centiva Capital first reported a position in AZN in Q3 2019 and held it in 12 quarters. The position peaked at $1.6M in Q1 2022. 1,383 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Centiva Capital reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • Centiva Capital sold 3,098 AstraZeneca shares in Q1 2026, an estimated $570K.
  • Centiva Capital first reported a position in AstraZeneca in Q3 2019 and held it in 12 quarters.
  • Centiva Capital's AstraZeneca position peaked at $1.6M in Q1 2022.
  • 1,383 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Centiva Capital's 13F filing for Q1 2026, filed 14 May 2026.